Page last updated: 2024-12-07

(4-fluoro-3-iodobenzyl)guanidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(4-Fluoro-3-iodobenzyl)guanidine is a **small molecule** that acts as a **potent and selective inhibitor** of the enzyme **protein arginine methyltransferase 5 (PRMT5)**.

**Here's a breakdown of its significance in research:**

**What is PRMT5?**

* PRMT5 is an enzyme that plays a crucial role in **modifying proteins** by adding a methyl group to arginine residues.
* This process, known as **methylation**, can significantly alter a protein's function and interaction with other molecules.
* PRMT5 is implicated in various cellular processes, including:
* **Transcriptional regulation**
* **RNA splicing**
* **DNA replication**
* **Cell cycle progression**
* **Immune response**

**Why is (4-fluoro-3-iodobenzyl)guanidine important?**

* **PRMT5 as a Drug Target:** PRMT5 has emerged as a potential therapeutic target for various diseases, including:
* **Cancer:** PRMT5 is often overexpressed in cancer cells and contributes to their growth and survival.
* **Autoimmune disorders:** Dysregulation of PRMT5 has been linked to autoimmune diseases like lupus.
* **Neurological disorders:** PRMT5 is involved in processes related to neurodevelopment and synaptic function, making it relevant for neurological disorders.

* **(4-fluoro-3-iodobenzyl)guanidine as a Research Tool:** This molecule acts as a potent and selective inhibitor of PRMT5, providing researchers with a valuable tool to:
* **Investigate PRMT5 function:** Studying how PRMT5 inhibition affects various cellular processes can shed light on its role in health and disease.
* **Develop new drugs:** By understanding how (4-fluoro-3-iodobenzyl)guanidine interacts with PRMT5, scientists can design and develop more effective and specific inhibitors for therapeutic applications.

**Key Features of (4-fluoro-3-iodobenzyl)guanidine:**

* **Potency:** It effectively inhibits PRMT5 activity at low concentrations.
* **Selectivity:** It primarily targets PRMT5, minimizing off-target effects.
* **Chemical Structure:** Its specific structure allows for binding to the active site of PRMT5, inhibiting its enzymatic activity.

**Overall, (4-fluoro-3-iodobenzyl)guanidine is a valuable research tool for understanding PRMT5 function and developing new therapeutic strategies for diseases where PRMT5 dysregulation plays a role.**

(4-fluoro-3-iodobenzyl)guanidine: a potential MIBG analog for positron emission tomography; structure given in first source; RN refers to (18F)-labelled compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID133057
CHEMBL ID121067
SCHEMBL ID14137984
MeSH IDM0238010

Synonyms (17)

Synonym
guanidine, ((4-(fluoro-18f)-3-iodophenyl)methyl)-
((4-(fluoro-18f)-3-iodophenyl)methyl)guanidine
(4-fluoro-3-iodobenzyl)guanidine
4-fibg
(4-(18f)fluoro-3-iodobenzyl)guanidine
159719-55-8
n-(4-fluoro-3-iodobenzyl)guanidine
CHEMBL121067
2-[(4-fluoro-3-iodophenyl)methyl]guanidine
SCHEMBL14137984
4-fluoro-3-iodobenzylguanidine
1-(4-fluoro-3-iodobenzyl)guanidine
117423-43-5
DTXSID50166721
159719-59-2
D88116
n''-[(4-fluoro-3-iodophenyl)methyl]guanidine
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (43)

Assay IDTitleYearJournalArticle
AID18949Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice adrenals after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18952Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice blood after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18948Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice adrenals after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19162Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice large intestine after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18954Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice bone after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19179Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice stomach after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19172Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice muscle after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19170Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice muscle after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19183Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice thyroid after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19155Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice heart after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19166Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice liver after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19176Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice spleen after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19161Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice large intestine after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19171Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice muscle after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19175Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice small intestine after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19169Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice lungs after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19167Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice lungs after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19177Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice spleen after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19160Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice kidney after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19156Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice heart after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19164Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice liver after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19181Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice stomach after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18950Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice adrenals after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19152Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice brain after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19182Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice thyroid after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19157Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice heart after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19178Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice spleen after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19180Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice stomach after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18953Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice blood after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19184Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice thyroid after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID202480The compound was tested for the concentration of inhibition by unlabelled analogues to SK-N-SH human neuroblastoma cells1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19154Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice brain after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19174Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice small intestine after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19173Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice small intestine after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19163Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice large intestine after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19151Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice bone after 4 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19158Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice kidney after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19165Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice liver after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID18951Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice blood after 1 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19168Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice lungs after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19150Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice bone after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19159Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice kidney after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
AID19153Tissue distribution expressed as percentage injected dose per gram of tissue in normal mice brain after 2 hour1994Journal of medicinal chemistry, Oct-14, Volume: 37, Issue:21
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.29 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]